Table 3 Regression coefficients (β) with 95% confidence intervals from multivariate logistic regression analyses on the effect of the GSTM1-null genotype, GSTTnull genotype, GSTM1-null/GSTT-null genotype and cumulative amount of OX, on the presence of SOS (0=absent–mild, 1= moderate–severe)

From: Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer

Prognostic factors

SOS regression coefficient (95% CI)

P- value

GSTM1-null genotype

−1.690 (0.042–0.817)

0.026*

GSTT1-null genotype

−0.617 (0.041–7.072)

0.638

GSTM1- and GSTT1-null genotype

0.429 (0.051–46.14)

0.805

Cumulative dose OX (mg m−2)

0.002 (1.000–1.004)

0.105

Additional BV

−1.068 (0.087–1.352)

0.126

  1. Abbreviations: BV=bevacizumab; CI, confidence interval; GSTM=glutathione S-transferase enzyme μ; GSTT=glutathione S-transferase enzyme θ; OX=oxaliplatin; SOS=sinusoidal obstruction syndrome.
  2. * indicates significance.
Back to article page